Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank Disease ID
1 African trypanosomiasis 💬
 [4] IL10, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
2 African trypanosomiasis 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
3 African trypanosomiasis 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
4 African trypanosomiasis 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
5 AGE-RAGE signaling pathway in diabetic complications 💬
 [5] CCL2, IL1A, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
6 AGE-RAGE signaling pathway in diabetic complications 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
7 AGE-RAGE signaling pathway in diabetic complications 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
8 AGE-RAGE signaling pathway in diabetic complications 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
9 Alcoholic liver disease 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
10 Alcoholic liver disease 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
11 Alcoholic liver disease 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
12 Alcoholic liver disease 💬
 [3] IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
13 Alzheimer disease 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
14 Alzheimer disease 💬
 [4] IL1A, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
15 Alzheimer disease 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
16 Alzheimer disease 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
17 Amoebiasis 💬
 [4] IL10, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
18 Amoebiasis 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
19 Amoebiasis 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
20 Amoebiasis 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
21 Antifolate resistance 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
22 Antifolate resistance 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
23 Antifolate resistance 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
24 Antifolate resistance 💬
 [3] IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
25 C-type lectin receptor signaling pathway 💬
 [4] IL10, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
26 C-type lectin receptor signaling pathway 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
27 C-type lectin receptor signaling pathway 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
28 C-type lectin receptor signaling pathway 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
29 Chagas disease 💬
 [5] CCL2, IL10, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
30 Chagas disease 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
31 Chagas disease 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
32 Chagas disease 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
33 Coronavirus disease - COVID-19 💬
 [4] CCL2, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
34 Coronavirus disease - COVID-19 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
35 Coronavirus disease - COVID-19 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
36 Coronavirus disease - COVID-19 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
37 Cytokine-cytokine receptor interaction 💬
 [6] CCL2, IL10, IL1A, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
38 Cytokine-cytokine receptor interaction 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
39 Cytokine-cytokine receptor interaction 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
40 Cytokine-cytokine receptor interaction 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
41 Cytosolic DNA-sensing pathway 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
42 Cytosolic DNA-sensing pathway 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
43 Cytosolic DNA-sensing pathway 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
44 Cytosolic DNA-sensing pathway 💬
 [2] IL1B, IL6 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
45 Fluid shear stress and atherosclerosis 💬
 [4] CCL2, IL1A, IL1B, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
46 Fluid shear stress and atherosclerosis 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
47 Fluid shear stress and atherosclerosis 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
48 Fluid shear stress and atherosclerosis 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
49 Graft-versus-host disease 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
50 Graft-versus-host disease 💬
 [4] IL1A, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
51 Graft-versus-host disease 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
52 Graft-versus-host disease 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
53 Hematopoietic cell lineage 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
54 Hematopoietic cell lineage 💬
 [4] IL1A, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
55 Hematopoietic cell lineage 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
56 Hematopoietic cell lineage 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
57 Herpes simplex virus 1 infection 💬
 [4] CCL2, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
58 Herpes simplex virus 1 infection 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
59 Herpes simplex virus 1 infection 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
60 Herpes simplex virus 1 infection 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
61 Human cytomegalovirus infection 💬
 [4] CCL2, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
62 Human cytomegalovirus infection 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
63 Human cytomegalovirus infection 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
64 Human cytomegalovirus infection 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
65 IL-17 signaling pathway 💬
 [4] CCL2, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
66 IL-17 signaling pathway 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
67 IL-17 signaling pathway 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
68 IL-17 signaling pathway 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
69 Inflammatory bowel disease 💬
 [5] IL10, IL1A, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
70 Inflammatory bowel disease 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
71 Inflammatory bowel disease 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
72 Inflammatory bowel disease 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
73 Inflammatory mediator regulation of TRP channels 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
74 Inflammatory mediator regulation of TRP channels 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
75 Inflammatory mediator regulation of TRP channels 💬
 [1] IL1B 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
76 Inflammatory mediator regulation of TRP channels 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
77 Influenza A 💬
 [5] CCL2, IL1A, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
78 Influenza A 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
79 Influenza A 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
80 Influenza A 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
81 Legionellosis 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
82 Legionellosis 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
83 Legionellosis 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
84 Legionellosis 💬
 [3] IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
85 Leishmaniasis 💬
 [4] IL10, IL1A, IL1B, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
86 Leishmaniasis 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
87 Leishmaniasis 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
88 Leishmaniasis 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
89 Lipid and atherosclerosis 💬
 [4] CCL2, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
90 Lipid and atherosclerosis 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
91 Lipid and atherosclerosis 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
92 Lipid and atherosclerosis 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
93 Malaria 💬
 [5] CCL2, IL10, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
94 Malaria 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
95 Malaria 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
96 Malaria 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
97 MAPK signaling pathway 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
98 MAPK signaling pathway 💬
 [3] IL1A, IL1B, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
99 MAPK signaling pathway 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
100 MAPK signaling pathway 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
101 Measles 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
102 Measles 💬
 [3] IL1A, IL1B, IL6 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
103 Measles 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
104 Measles 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
105 Necroptosis 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
106 Necroptosis 💬
 [3] IL1A, IL1B, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
107 Necroptosis 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
108 Necroptosis 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
109 NF-kappa B signaling pathway 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
110 NF-kappa B signaling pathway 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
111 NF-kappa B signaling pathway 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
112 NF-kappa B signaling pathway 💬
 [2] IL1B, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
113 NOD-like receptor signaling pathway 💬
 [4] CCL2, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
114 NOD-like receptor signaling pathway 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
115 NOD-like receptor signaling pathway 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
116 NOD-like receptor signaling pathway 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
117 Non-alcoholic fatty liver disease 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
118 Non-alcoholic fatty liver disease 💬
 [4] IL1A, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
119 Non-alcoholic fatty liver disease 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
120 Non-alcoholic fatty liver disease 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
121 Osteoclast differentiation 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
122 Osteoclast differentiation 💬
 [3] IL1A, IL1B, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
123 Osteoclast differentiation 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
124 Osteoclast differentiation 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
125 Pathogenic Escherichia coli infection 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
126 Pathogenic Escherichia coli infection 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
127 Pathogenic Escherichia coli infection 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
128 Pathogenic Escherichia coli infection 💬
 [3] IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
129 Pathways of neurodegeneration - multiple diseases 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
130 Pathways of neurodegeneration - multiple diseases 💬
 [4] IL1A, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
131 Pathways of neurodegeneration - multiple diseases 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
132 Pathways of neurodegeneration - multiple diseases 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
133 Pertussis 💬
 [5] IL10, IL1A, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
134 Pertussis 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
135 Pertussis 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
136 Pertussis 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
137 Prion disease 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
138 Prion disease 💬
 [4] IL1A, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
139 Prion disease 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
140 Prion disease 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
141 Rheumatoid arthritis 💬
 [5] CCL2, IL1A, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
142 Rheumatoid arthritis 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
143 Rheumatoid arthritis 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
144 Rheumatoid arthritis 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
145 Salmonella infection 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
146 Salmonella infection 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
147 Salmonella infection 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
148 Salmonella infection 💬
 [3] IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
149 Shigellosis 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
150 Shigellosis 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
151 Shigellosis 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
152 Shigellosis 💬
 [2] IL1B, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
153 Th17 cell differentiation 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
154 Th17 cell differentiation 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
155 Th17 cell differentiation 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
156 Th17 cell differentiation 💬
 [2] IL1B, IL6 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
157 TNF signaling pathway 💬
 [4] CCL2, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
158 TNF signaling pathway 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
159 TNF signaling pathway 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
160 TNF signaling pathway 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
161 Toll-like receptor signaling pathway 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
162 Toll-like receptor signaling pathway 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
163 Toll-like receptor signaling pathway 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
164 Toll-like receptor signaling pathway 💬
 [3] IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
165 Tuberculosis 💬
 [5] IL10, IL1A, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
166 Tuberculosis 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
167 Tuberculosis 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
168 Tuberculosis 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
169 Type I diabetes mellitus 💬
 [2] IL1A, IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬
170 Type I diabetes mellitus 💬
 [3] IL1A, IL1B, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
171 Type I diabetes mellitus 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
172 Type I diabetes mellitus 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
173 Yersinia infection 💬
 [5] CCL2, IL10, IL1B, IL6, TNF 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
174 Yersinia infection 💬
 [1] IL1B 💬 Canakinumab 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
175 Yersinia infection 💬
 [1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
176 Yersinia infection 💬
 [1] IL1B 💬 Rilonacept 💬 Rilonacept [4] 51, 106, 107, 266 💬

Back to top